 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | M201-A / AETAS Pharma, ABI-M201 / Assembly Biosci
Journal: Phylogenetic history of patrilineages rare in northern and eastern Europe from large-scale re-sequencing of human Y-chromosomes. (Pubmed Central) - Mar 24, 2022
We assess the possible direction of influx of ancestral carriers for some of these male lineages. In addition, we demonstrate the congruency of paternal haplogroup composition of our dataset with two independent population-based cohorts from Estonia and Sweden.
- || M201-A / AETAS Pharma
Trial completion: First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - Nov 30, 2021
P1, N=40, Completed, Sponsor: Yuji KUMAGAI
In addition, we demonstrate the congruency of paternal haplogroup composition of our dataset with two independent population-based cohorts from Estonia and Sweden. Recruiting --> Completed
- || M201-A / AETAS Pharma
Trial completion: Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - Aug 31, 2021
P1, N=18, Completed, Sponsor: Kitasato University
Recruiting --> Completed Recruiting --> Completed
- | M201-A / AETAS Pharma
New P2 trial: First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation (clinicaltrials.gov) - Oct 30, 2020
P2, N=42, Recruiting, Sponsor: Kitasato University
- | MP201 / Mitochon, M201-A / AETAS Pharma
Preclinical, Journal: A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson's disease. (Pubmed Central) - Sep 13, 2020
Amelioration of motor deficits and dopamine neuron loss by MP201 treatment was associated with reductions in microglial and astrocyte activation and neuroinflammation. These preclinical findings suggest the potential application of mitochondrial uncoupling agents such as MP201 as disease-modifying therapies for PD.
- | M201-A / AETAS Pharma
New P1 trial: Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - Jul 8, 2020
P1, N=9, Recruiting, Sponsor: Kitasato University
- | M201-A / AETAS Pharma
Enrollment open: First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - Mar 17, 2017
P1, N=56, Recruiting, Sponsor: Yuji KUMAGAI
These preclinical findings suggest the potential application of mitochondrial uncoupling agents such as MP201 as disease-modifying therapies for PD. Not yet recruiting --> Recruiting
- | M201-A / AETAS Pharma
New P1 trial: First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects (clinicaltrials.gov) - Feb 16, 2017
P1, N=56, Not yet recruiting, Sponsor: Yuji KUMAGAI